Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis
Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis
复制标题
DOI：
10.1007/s10549-012-2364-2
复制
发表时间：
2013-01-01
影响因子：
3.8
通讯作者：
Ozcelik, Hilmi
中科院分区：
文献类型：
--
作者：
Pabalan, Noel;Jarjanazi, Hamdi;Ozcelik, Hilmi
BRCA 1相互作用蛋白1（BRIP 1）基因中Pro 919 Ser多态性与乳腺癌之间报道的关联的不一致性促使我们进行荟萃分析。虽然研究较少，但我们也研究了与另外两种BRIP 1多态性（C47 G和G64 A）和乳腺癌风险相关的风险。对来自8项已发表的病例对照研究的5，122例病例和5，735例对照的个体数据进行了Pro 919 Ser多态性评价。因此，C47 G和G64 A多态性分别在1,539例病例和1,183例对照中进行了研究，667例和782例对照中进行了研究。在总体分析中，Pro 919 Ser多态性与乳腺癌风险之间缺乏关联（比值比[OR] 0.98-1.02），当仅限于欧洲血统的受试者（OR 0.96-1.03）或甚至在高效能研究（OR 0.97-1.03）中时，基本不变。在绝经亚组中，绝经前妇女的Pro和Ser等位基因对比遵循空模式（OR 0.94-0.98），但Pro-Ser基因型比较则不遵循空模式，观察到Pro-Ser基因型比较的风险显著增加（OR 1.39，P = 0.002）。绝经后妇女（> 50岁）表现出一系列的合并效应，从Pro-Ser基因型的保护（OR 0.83，P = 0.11）到Pro和Ser等位基因比较的风险轻微增加（OR 1.12-1.16，P = 0.28-0.42）。G64 A多态性效应基本为零（OR 0.90-0.98），但在所有遗传模型下发现C47 G多态性均无显著增加风险（OR 1.27-1.40）。绝经前的发现和绝经后妇女的可变结局需要更多的研究来证实。
Inconsistency of reported associations between the Pro919Ser polymorphism in the BRCA1 interacting protein 1 (BRIP1) gene and breast cancer prompted us to undertake a meta-analysis. Although investigated by fewer studies, we have also studied the risk associated with the two additional BRIP1 polymorphisms, C47G and G64A, and breast cancer riskWe conducted searches of the published literature in MEDLINE through PubMed up to October 2012. Individual data on 5,122 cases and 5,735 controls from eight published case-control studies were evaluated for the Pro919Ser polymorphism. Accordingly, C47G and G64A polymorphisms were studied in 1,539 cases and 1,183 controls, and 667 and 782, respectively.In the overall analysis, association was lacking between the Pro919Ser polymorphism and breast cancer risk (odds ratio [OR] 0.98-1.02), materially unchanged when confined to subjects of European ancestry (OR 0.96-1.03) or even in the high-powered studies (OR 0.97-1.03). In the menopausal subgroups, premenopausal women followed the null pattern (OR 0.94-0.98) for the Pro and Ser allele contrasts, but not for the Pro-Ser genotype comparison where significant increased risk was observed (OR 1.39, P = 0.002). The postmenopausal women (> 50 years) exhibited a range of pooled effects from protection (OR 0.83, P = 0.11) in the Pro-Ser genotype to slightly increased risk (OR 1.12-1.16, P = 0.28-0.42) in the Pro and Ser allele comparisons. The G64A polymorphism effects were essentially null (OR 0.90-0.98), but C47G was found to confer non-significantly increased risk under all genetic models (OR 1.27-1.40).Upon conclusion, overall summary estimates imply no associations but suggest susceptibility among carriers of the C47G polymorphism and Pro-Ser genotype in premenopausal women. The premenopausal findings and variable outcomes in postmenopausal women require more studies for confirmation.